Vanda Pharmaceuticals Inc.
VNDANext catalyst
Imsidolimab
Acne Vulgaris
Get an email about VNDA's next catalysts
Track Vanda Pharmaceuticals (VNDA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (Phase 2 readout, Phase 3 readout).See the timeline
5 upcoming, 2 past
Tradipitant Phase 3 Est. Readout
Primary completion for Tradipitant trial (NCT07446439) in Nausea and Vomiting
Phase III trial failed; Vanda is pausing development of the anxiety drug.
SourceFDA PDUFA Date imsidolimab
bla filing. Extracted from SEC filing: EX-99.1
SourceVQW-765 Phase 3 Est. Readout
Primary completion for VQW-765 trial (NCT07221578) in Social Anxiety Disorder (SAD)
Late-stage study failed to meet primary endpoint
SourceVCA-894A Phase 2 Est. Readout
Estimated primary completion for VCA-894A trial (NCT07223632) in Charcot Marie Tooth Disease (CMT). Topline data typically follows completion by weeks to months.
SourceTradipitant Phase 3 Est. Readout
Primary completion for Tradipitant trial (NCT06138613) in Motion Sickness
SourceHow VNDA's past catalysts played out
Market Overview
Stock performance and key metrics
Tasimelteon Oral Suspension
Insomnia Disorder
Ponesimod
Moderate-to-severe Chronic Plaque Psoriasis
Imsidolimab
Acne Vulgaris
Ziprasidone
Schizophrenia
Tasimelteon
Sleep Wake Disorders
Milsaperidone
Major Depressive Disorder (MDD)
iloperidone
Schizophrenia
Open Label Tradipitant
Idiopathic Gastroparesis
Imsidolimab high dose
Generalized Pustular Psoriasis
VQW-765
Performance Anxiety
VEC-162
Circadian Rhythm Sleep Disorders
Tradipitant
Motion Sickness
Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension
Autism Spectrum Disorder
Trichostatin A
Onychomycosis of Toenail
VCA-894A
Charcot Marie Tooth Disease (CMT)
VSF-173
Excessive Somnolence
Oral iloperidone
Schizophrenia
Iloperidone microparticle formulation
Schizophrenia
VLY-686 (Tradipitant)
Gastroparesis
VLY-686
Treatment-resistant Pruritus Associated With Atopic Dermatitis
VSJ-110
Dry Eye
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Tasimelteon Oral Suspension | Phase 3 | Insomnia Disorder | - | - |
Ponesimod | Phase 3 | Moderate-to-severe Chronic Plaque Psoriasis | - | - |
Imsidolimab | Phase 3 | Acne Vulgaris | - | - |
Ziprasidone | Phase 3 | Schizophrenia | - | - |
Tasimelteon | Phase 3 | Sleep Wake Disorders | - | - |
Milsaperidone | Phase 3 | Major Depressive Disorder (MDD) | - | - |
iloperidone | Phase 3 | Schizophrenia | - | - |
Open Label Tradipitant | Phase 3 | Idiopathic Gastroparesis | - | - |
Imsidolimab high dose | Phase 3 | Generalized Pustular Psoriasis | - | - |
VQW-765 | Phase 3 | Performance Anxiety | - | - |
VEC-162 | Phase 3 | Circadian Rhythm Sleep Disorders | - | - |
Tradipitant | Phase 3 | Motion Sickness | - | - |
Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension | Phase 3 | Autism Spectrum Disorder | - | - |
Trichostatin A | Phase 2 | Onychomycosis of Toenail | - | - |
VCA-894A | Phase 2 | Charcot Marie Tooth Disease (CMT) | - | - |
VSF-173 | Phase 2 | Excessive Somnolence | - | - |
Oral iloperidone | Phase 2 | Schizophrenia | - | - |
Iloperidone microparticle formulation | Phase 2 | Schizophrenia | - | - |
VLY-686 (Tradipitant) | Phase 2 | Gastroparesis | - | - |
VLY-686 | Phase 2 | Treatment-resistant Pruritus Associated With Atopic Dermatitis | - | - |
VSJ-110 | Phase 2 | Dry Eye | - | - |
Generalized Pustular Psoriasis
1 drug in this indication
prevention of vomiting induced by motion
1 drug in this indication
Acute Anxiety
1 drug in this indication
social anxiety disorder
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Vanda Pharmaceuticals Inc.'s drug pipeline?→
CatalystAlert tracks 21 drug candidates in Vanda Pharmaceuticals Inc.'s (VNDA) pipeline across Phase 3, Phase 2. Its lead program is Imsidolimab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Vanda Pharmaceuticals Inc.'s next FDA catalyst?→
Vanda Pharmaceuticals Inc.'s (VNDA) next tracked catalyst is a PDUFA date expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track VNDA biotech catalysts?→
Add VNDA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Vanda Pharmaceuticals Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.